CHG0521 Oral Coating in Patients with Solid Tissue Tumor/Recurrent/Metastatic TSCC
This is a prospective single-arm loading test study of CHG0521 oral coating in patients with solid tissue tumor/recurrent/metastatic TSCC
Squamous Cell Carcinoma|Squamous Cell Carcinoma of the Oral Cavity
DRUG: CHG0521 Oral Coating
Objective Response Rate (ORR), ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least 30% decrease in the sum of diameters of target lesions) per RECIST 1.1., 24 weeks
QOL, Washington Quality of Life Score, 24 weeks|PCR, Pathologic Complete Response, 24 weeks|DRR, Disease Recurrence Rate, 24 weeks|OS, Overall Survival, 1 year|AEs, Incidence and severity of adverse events, 1 year
This is a prospective single-arm loading test study of CHG0521 oral coating in patients with solid tissue tumor/recurrent/metastatic TSCC